Verastem, Inc. Finite-Lived Intangible Asset, Expected Amortization, Year One
Verastem, Inc. (VSTM) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $1.12 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-08-06
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $1.12M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $1.12M.
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $1.12M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $1.12M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2026-06-30 | $1.12M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.12M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $1.12M 10-K · filed 2026-03-04 |
| 2025-09-30 | $1.12M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $515.00K 10-Q · filed 2025-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |